Pharmazz
Pharmazz, Inc. is an innovative biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics for critical care medicine. It has a promising drug pipeline, including products like Lyfaquin® (Centhaquine) and Sovateltide, targeting conditions such as hypovolemic shock, cerebral ischemic stroke, Alzheimer's disease, and other neurodegenerative disorders. The company emphasizes first-in-class products with unique mechanisms of action, backed by extensive clinical development and a seasoned management team. Pharmazz operates in the USA, India, and UK, with collaborations and licensing agreements with academic institutions and regulatory approvals for its products in various stages of clinical trials and market authorization.
Industries
Nr. of Employees
medium (51-250)
Pharmazz
Willowbrook, Illinois, United States, North America
Products
Centhaquine (resuscitative agent for hypovolemic shock)
A small‑molecule resuscitative agent acting on adrenergic receptors to increase venous return, improve cardiac output and tissue perfusion; evaluated in preclinical models and randomized clinical trials and authorized for marketing in India.
Sovateltide (endothelin‑B receptor agonist for CNS indications)
A selective endothelin‑B receptor agonist developed for neuroprotection and neuroregeneration; demonstrated effects on cerebral blood flow, anti‑apoptotic and antioxidant activity, angiogenesis and neurogenesis in preclinical studies and evaluated in Phase I–III clinical trials for ischemic stroke and other CNS indications.
Lyfaquin
Centhaquine (Lyfaquin) is a highly effective resuscitative agent developed to treat hypovolemic shock by enhancing venous return and returning blood to active circulation.
Centhaquine
A novel resuscitative agent that increases cardiac output and reverses shock without inducing dangerous arterial constriction, delivered via a standard peripheral IV.
Sovateltide
Sovateltide is an endothelin-B (ETB) receptor agonist researched and developed for the treatment of Alzheimer's disease to promote neurogenesis, angiogenesis, and repair damaged brain tissue.
PMZ-2123
A drug candidate being developed by Pharmazz for the treatment of an undisclosed indication.
Centhaquine (resuscitative agent for hypovolemic shock)
A small‑molecule resuscitative agent acting on adrenergic receptors to increase venous return, improve cardiac output and tissue perfusion; evaluated in preclinical models and randomized clinical trials and authorized for marketing in India.
Sovateltide (endothelin‑B receptor agonist for CNS indications)
A selective endothelin‑B receptor agonist developed for neuroprotection and neuroregeneration; demonstrated effects on cerebral blood flow, anti‑apoptotic and antioxidant activity, angiogenesis and neurogenesis in preclinical studies and evaluated in Phase I–III clinical trials for ischemic stroke and other CNS indications.
Lyfaquin
Centhaquine (Lyfaquin) is a highly effective resuscitative agent developed to treat hypovolemic shock by enhancing venous return and returning blood to active circulation.
Centhaquine
A novel resuscitative agent that increases cardiac output and reverses shock without inducing dangerous arterial constriction, delivered via a standard peripheral IV.
Sovateltide
Sovateltide is an endothelin-B (ETB) receptor agonist researched and developed for the treatment of Alzheimer's disease to promote neurogenesis, angiogenesis, and repair damaged brain tissue.
PMZ-2123
A drug candidate being developed by Pharmazz for the treatment of an undisclosed indication.
Services
Design and conduct of clinical trials including site selection, initiation, monitoring, data management and regulatory compliance support.
Execution of in vivo efficacy and safety studies across multiple disease models including hemorrhagic shock, stroke, cardiac arrest and neonatal HIE.
Development and characterization of small‑molecule formulations and evaluation of liposomal nanocarriers in preclinical assays.
Regulatory strategy, dossier preparation and market authorization support across India, US and Europe (via regional subsidiary).
Structuring licensing agreements, academic collaborations and strategic equity/marketing partnerships.
Design and conduct of clinical trials including site selection, initiation, monitoring, data management and regulatory compliance support.
Execution of in vivo efficacy and safety studies across multiple disease models including hemorrhagic shock, stroke, cardiac arrest and neonatal HIE.
Development and characterization of small‑molecule formulations and evaluation of liposomal nanocarriers in preclinical assays.
Regulatory strategy, dossier preparation and market authorization support across India, US and Europe (via regional subsidiary).
Structuring licensing agreements, academic collaborations and strategic equity/marketing partnerships.
Expertise Areas
- Clinical trial management
- Neuroregeneration and CNS therapeutics
- Resuscitation and critical care therapeutics
- Preclinical models and translational research
Key Technologies
- Endothelin‑B receptor agonist therapeutics
- Alpha‑2B adrenergic receptor agonist therapeutics
- Animal models (rodent, swine, neonatal)
- In vitro neuronal progenitor and neuroblastoma assays